LFCR LIFECORE BIOMEDICAL, INC. \DE\
Pharmaceutical Preparations · Nasdaq · SEC CIK 1005286 · Fiscal year ends 05/25
Financial factors as of 2025-05-25 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.5%
TTM net income YoY-422.3%
TTM EPS YoY-484.8%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin31.3%
Operating margin-13.4%
Net margin-30.0%
FCF margin-10.6%
EBITDA margin-7.2%
Returns
ROE-612.1%
ROA-15.7%
ROIC (approx.)-10.7%
Asset turnover0.52x
Leverage & solvency
Liabilities / assets80.2%
Debt / equity100.20x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.00x
Accruals ratio-15.6%
Payout ratio—
Capex / revenue10.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-05-25 | FY20242024-05-26 |
|---|---|---|
| Income statement | ||
| Revenue | $128.87M | $128.26M |
| Cost of revenue | $88.57M | $86.41M |
| Gross profit | $40.30M | $41.85M |
| R&D expense | $8.26M | $8.57M |
| SG&A expense | $44.05M | $40.46M |
| Operating income | -$17.25M | -$8.84M |
| Interest expense | $22.17M | $18.15M |
| Pretax income | -$38.67M | $9.51M |
| Income tax | $43,000 | $183,000 |
| Net income | -$38.72M | $12.01M |
| EBITDA | -$9.22M | -$890,000 |
| EPS (basic) | -1.27 | 0.39 |
| EPS (diluted) | -1.27 | 0.33 |
| Weighted avg. shares (diluted) | 34.82M | 36.66M |
| Balance sheet | ||
| Cash & equivalents | $8.27M | $8.46M |
| Receivables | — | $31.15M |
| Inventory | $32.29M | $39.98M |
| Current assets | $85.68M | $81.03M |
| PP&E, net | $129.01M | $149.16M |
| Goodwill | $13.88M | $13.88M |
| Intangibles | $4.20M | $4.20M |
| Total assets | $239.34M | $253.96M |
| Current liabilities | $30.18M | $38.87M |
| Short-term debt | $3.44M | $943,000 |
| Long-term debt | $130.44M | $124.67M |
| Total debt | $133.87M | $125.61M |
| Total liabilities | $191.91M | $200.06M |
| Shareholders' equity | $1.34M | $11.31M |
| Net debt | $125.61M | $117.15M |
| Shares outstanding | 37.03M | 30.56M |
| Cash flow statement | ||
| Operating cash flow | -$206,000 | $257,000 |
| Capital expenditure | $13.41M | $18.39M |
| Free cash flow | -$13.62M | -$18.14M |
| Investing cash flow | -$6.42M | -$18.39M |
| Financing cash flow | $6.42M | $7.51M |
| Depreciation & amortization | $8.03M | $7.95M |
| Stock-based compensation | $10.16M | $6.20M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.